Molecular mediators such as intercellular adhesion molecule-1 (ICAM-1) have been implicated in the induction of neuronal damage after ischemia/reperfusion. However, the time-dependent expression of ICAM-1 after transient ischemia and the relative influence of ICAM-1 on neuronal cell death are not well understood. We performed immunostaining for ICAM-1 and apoptotic-like neuronal cell death by in situ by terminal UTP-nucleotide 3'-OH-DNA end labeling (TUNEL) after a 1-hr transient middle cerebral artery occlusion (tMCAO) in mouse. ICAM-1-like immunoreactivity (ICAM-1-ir) was detected only to a slight extent in the brains of sham-operated control. ICAM-1-ir after tMCAO was noted in the ischemic region of the ipsilateral hemisphere within 3 to 6 hr, and increased significantly from 24 to 96 hr. The ICAM-1-ir was mainly localized in the endothelium of blood vessels, and was also observed in astrocytes 24 hr after tMCAO. While the endothelial expression of ICAM-1-ir overlapped with that of TUNEL staining, the astroglial expression of ICAM-1-ir was observed around the periphery of infarction, which did not recognize TUNEL-positive reaction. These results suggest that ICAM-1 expression in the mouse brain increases after tMCAO, and that the endothelial expression of ICAM-1 could be indicative of the induction of neuronal damage via leukocyte invasion.
I. Introduction
Intercellular adhesion molecule-1 (ICAM-1), a member of the immunogloblin gene superfamily, binds with CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1) on the surface of leukocytes and is involved in the adhesion and transendothelial migration of leukocytes in inflammatory processes and during cerebral ischemia. The deteriorative properties of ICAM-1 that contribute to cerebral ischemia [3, 6, 11, 23] and neurodegenerative diseases such as multiple sclerosis (MS) and experimental allergic encephalitis (EAE) [15] have been reported in several papers, in addition to which clinical trials using ICAM-1 monoclonal antibody (Enlimomab) in the treatment of stroke victims have begun [5] . However, experimental evidence for the specific localization of ICAM-1 in the brain under pathological conditions has not been elucidated in detail. Therefore, we determined the expression and localization of ICAM-1 after transient middle cerebral artery occlusion (tMCAO) in the brains of mice using immunohistological techniques. Moreover, we performed double-immunostaining for ICAM-1 and in situ by terminal UTP nucleotide 3'-OH-DNA end labeling (TUNEL) for the identification of the infarct area in order to reveal the relationship between ICAM-1 and neuronal cell death.
II. Materials and Methods

Animals
All experimental procedures involving animals were approved by the Institutional Animal Care and Use Committee of Showa University (#02097). Adult male Balb/c
Correspondence to: Seiji Shioda, Ph.D., Department of Anatomy, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawaku, Tokyo 142-8555, Japan. strain mice aged 7 weeks were purchased from SLC Japan (Shizuoka, Japan). All mice were maintained on a 12-hr light/dark cycle at 23±2°C with constant humidity (40± 15%).
Induction of tMCAO
Adult male mice weighing 25 to 27.5 g (8 to 11 weeks of age) were placed under deep anesthesia by 2.5% sevoflurane in N 2 O/O 2 (70/30%) and subjected to focal cerebral ischemia by intraluminal middle cerebral artery (MCA) occlusion with nylon monofilament suture as described previously [17] . After a midline skin incision, the left external carotid artery (ECA) was exposed and its branches electrocoagulated. A 7-0 round tip nylon suture was then introduced into the internal carotid artery via the ECA stump, and advanced 8.5-10 mm distal to the carotid bifurcation to achieve the MCA occlusion. The suture was withdrawn through ECA one hour after the induction of ischemia. Animals that did not show grade 1 neurological symptoms at 1 hr after ischemia [7] , i.e. failure to extend the right forepaw, or those that hemorrhaged, were excluded from the experiment on the basis of technical error.
In a previous study, we showed that regional blood flow (rCBF) after ischemia was decreased to approximately 20% of the baseline level in this model. The rCBF was sustained during the ischemic episode, and recovered to levels ranging from 87 to 115% of baseline within 5 min after reperfusion had commenced [16] .
Immunohistochemistry for ICAM-1
Mice were anesthetized with sodium pentobarbital (50 mg/kg, i.p.) at 0 (sham-operated control), 3, 6, 12, 24, 48, or 96 hr after tMCAO, and perfused transcardially with 0.9% saline followed by 2% paraformaldehyde in 50 mM phosphate buffer (pH 7.4). Brains were then removed, postfixed overnight in same buffer and cryoprotected in 20% sucrose.
Sections were cut on a cryostat at a thickness of 8-mm and preincubated in 10% normal goat serum (NGS) after endogenous peroxidase blocking by 0.3% H2O2. They were then incubated overnight at 4°C with a hamster anti-mouse ICAM-1 monoclonal antibody (1:100, Chemicon, Temecula, CA) as the primary antibody. Thereafter, sections were rinsed and incubated with biotinylated goat anti-hamster IgG (1:200, Vector, Burlingame, CA) in PBS and then incubated in an avidin-biotin complex solution (Vector) followed by diaminobenzidine (DAB; Vector) as the chromogen. A control was performed in same way except to use PBS without the primary antibody Optical areas of ICAM-1 expression were semi-quantified on the basis of relative intensity of DAB staining in the slice. As shown in Fig. 1 , the optical areas of ICAM-1 expression in four different brain regions (two regions in the somatosensory cortex, one region in the piriform cortex, and one region in the striatum in a coronal section from the bregma 1.10 to -0.14 mm) from the ipsilateral hemisphere were evaluated by taking images with an objective lens (´40) and calculated using NIH Image software (1.62). The size of the photo-image was 820.5´615.4 mm 2 , and the optical area of ICAM-1 expression was shown as the percentage of total area of image. Two to five mice were examined at each time point. Data are expressed as mean± standard error. Statistical comparisons were made by oneway ANOVA with Dunnett's post hoc test compared to the sham-operated control (0 hr). Values of p<0.05 were considered to be statistically significant.
Double-staining by ICAM-1 and astrocyte
To identify the cell-types stained by the antibody for ICAM-1, multiple-staining with ICAM-1 and glial fibrillary acidic protein (GFAP) as a marker of astrocyte was performed. Sections were preincubated in 10% NGS after treatment by H 2 O 2 and then co-incubated with ICAM-1 antibody (1:100) and monoclonal mouse GFAP antibody (1:500, Sigma, St. Louis, MO) overnight at 4°C. The sections were then rinsed and immersed in Alexa 546-labeled goat anti-hamster IgG antibody and Alexa 488-labeled goat antimouse IgG antibody (1:800, Molecular Probes, Eugene, OR) as secondary antibodies. After counterstaining by 4',6-diamidine-2-phenylindole dihydrochloride (DAPI, 1:10000, Boehringer Mannheim, Manheim, Germany), the sections were enclosed. These experiments were performed on sections obtained from the brains of 2 to 3 mice at each time point (author: check). Sections were observed with the aid of a fluorescence microscope (Olympus AX-70; Olympus, Tokyo, Japan).
Double-staining by ICAM-1 and TUNEL
To determine the distribution of ICAM-1-like immunoreactivity (ICAM-1-ir) and the regions exhibiting neuronal cell death, double-staining by ICAM-1 and TUNEL assay was performed after 48 hr after tMCAO. TUNEL staining (In Situ Cell Death Detection Kit, POD; Roche, Manheim, Germany) was performed as described previously with minor modifications [15] . Following this, immunostaining of sections to identify ICAM-1-ir was performed as described above using Alexa 546-labeled secondary antibody.
III. Results
ICAM-1 immunoreactivity
There was almost no non-specific reaction of procedure without primary antibody as control section (data not shown). ICAM-1-ir was detected to a minimal extent in the brains of sham-operated control mice (Fig. 1A, D) . Increased ICAM-1-ir was noted in the ipsilateral hemispheres of tMCAO-operated mice 3 to 6 hr (Fig. 1E, F) after the ischemic episode. More prominent ICAM-1-ir was observed in the ischemic core 12 to 24 hr (Fig. 1B, G, H) after tMCAO, with a sustained elevated expression from 48 to 96 hr (Fig. 1C, I, J) . ICAM-1-ir was increased slightly in the contralateral hemisphere over the period of the experiment; 96 hr after tMCAO ICAM-1-ir in the contralateral hemisphere remained at a level comparable to that seen in the ipsilateral hemisphere 3 to 6 hr after tMCAO (data not shown). Results of the semi-quantification of the percentage of optical area of ICAM-1 expression in the ipsilateral hemisphere are provided in Fig. 2 and show that the density of ICAM-1-ir progressively increased in a time-dependent matter after tMCAO. A significant increase in ICAM-1-ir was found at 24 (4.25±0.35%, p<0.05), 48 (5.69±1.29%, p<0.01) and 96 hr (7.18±0.83%, p<0.001) post-tMCAO compared to the sham-operated controls (1.99±0.36%). The increase in ICAM-1-ir at the 96 hr time point after tMCAO was 3.6-fold higher than that seen in sham-operated controls.
ICAM-1-ir was mainly observed in the endothelial cells of blood vessels (Fig. 1K) . Endothelial ICAM-1 expression was observed over an area similar to that of the infarct area. Twenty-four hours after the ischemic episode, ICAM-1-ir was also expressed in glial-like cells (Fig. 1M ) located at the periphery of the infarct area, that is, in the penumbra. To confirm that it was glial-like cells that expressed ICAM-1-ir, multiple-staining for ICAM-1 and GFAP was performed. GFAP-ir as a marker of reactive astrocytes was clearly observed in the penumbra and its outer region 24 hr after tMCAO (data not shown). The ICAM-1-ir in glial-like cells was highly co-localized with the GFAP-ir expressed in the penumbra (Fig. 3A-D) . Co-localization of ICAM-1-ir and GFAP-ir was not observed in infarct area, which ICAM-1-ir has noted in the endothelial cells of blood vessel (data not shown).
To determine the relation between regions displaying ICAM-1-ir and those exhibiting apoptotic-like neuronal cell death after ischemia, immunostaining for ICAM-1 and TUNEL was performed. As expected from the above results, although the region of endothelial ICAM-1-ir expression ICAM-1-ir overlapped with that of TUNEL staining, the expression of astroglial ICAM-1-ir did not (Fig. 4) . 
IV. Discussion
In the present study we have determined that ICAM-1-ir increased significantly in endothelial cells of the capillaries and blood vessels of brain slices after tMCAO in mice. The ICAM-1-ir also co-localized with GFAP-positive cells, which is to say that ICAM-1 was expressed in reactive astrocytes. The astroglial expression of ICAM-1-ir was observed 24 hr after tMCAO and extended along the penumbra of the infarct area. While the region of endothelial ICAM-1-ir overlapped with that exhibiting neuronal cell death as detected by TUNEL staining, astrogilal ICAM-1-ir did not overlap with TUNEL positive cells.
There is increasing evidence to suggest that ICAM-1 participates in the induction of ischemic neuronal cell death in the rodent [3, 11, 23] . The expression of ICAM-1 has been observed in the cerebral microvasculature subjected to cerebral ischemia in rodents [3, 10, 25, 26] and after brain infarction and cardiac arrest in humans [12] . ICAM-1 expression is enhanced in inflammatory diseases of the central nervous system (CNS), such as in the cases of MS and EAE, and expression of ICAM-1 has been detected in endothelial, astrocytic and microglial cells under pathological conditions [2, 4, 22, 24] . Other studies, providing evidence in support of a role for ICAM-1 in neuronal cells death, have shown that the infarct volume of brain tissue in ICAM-1 gene-deficient (KO) mice after permanent (p) and tMCAO is smaller than that measured in wild-type mice [3, 11] . Recently, a clinical trial was commenced to evaluate the efficacy of using anti-ICAM-1 antibodies (Enlimomab) in the treatment of ischemic stroke [5] . ICAM-1 binds with LFA-1 and Mac-1 of leukocytes and facilitates the adherence of leukocytes to endothelial cells. This supports the invasion of leukocytes towards the ischemic region [6, 15] . It is thought that the ICAM-1-facilitated leukocyte migration into the brain releases reactive oxygen species (ROS) such as the superoxide anion and nitric oxide, and that ROS aggravate ischemic damage [1, 11, 14] .
Other reports have shown that ICAM-1 is induced by the proinflammatory cytokines such as interleukin-1b (IL1b) and tumor necrosis factor-a (TNF-a) [8, 13, [25] [26] [27] [28] and down-regulated by immunosuppressive cytokines such as transforming growth factor-b1 (TGF-b1), IL-6 and IL-10 [18, 20, 21] . IL-1b converting enzyme (ICE) KO mice exhibited a diminished infarct volume after pMCAO and a reduced endothelial expression of ICAM-1 compared to wild-type mice [27] . Moreover, addition of an adenoviral vector encoding for human IL-1 receptor antagonist (IL-1ra) cDNA in mouse also diminished the infarct volume size and the number of ICAM-1-immunopositive vessels after tMCAO [25, 26] . Recently, we reported that IL-1 KO mice exhibited decreased neuronal cell death and decreased ROS generation after tMCAO and cardiac arrest as compared with wild-type mice [9, 16, 17] . In those reports, we also showed that immunoreactivity for the type-I IL-1 receptor appeared in the cerebral vasculature and not in the astrocytes of the ipsilateral hemisphere after tMCAO [17] . These results suggest that the endothelial expression of ICAM-1 might be regulated by IL-1 and contribute to the exacerbation of neuronal cell death and neurodegeneration.
There are no reports to date that have clearly shown that ICAM-1 is expressed in increased amounts in astrocytes after ischemia. The results presented here, however, using multi-staining techniques, clearly demonstrate that ICAM-1 is expressed in reactive astrocytes after tMCAO. Some evidence for such a process has been forthcoming from experiments using cultured cells. ICAM-1 was induced in astroglial cultures by TNF-a according to flow cytometry determination [13, 19] . In addition, in various diseases of the CNS, such as MS and EAE, ICAM-1 expression is exhibited in astrocytes [2, 4, 22, 24] . These previous reports support the present results showing that ICAM-1 is expressed in astrocytes. In MS and EAE, it is thought that the astroglial ICAM-1 supports the extravasation of leukocytes collaborating with endothelial ICAM-1 [15] . In our results, however, the astroglial expression ICAM-1 after ischemia did not overlap with the endothelial expression ICAM-1 and was not observed in the infarct area. There is no evidence that astroglial ICAM-1 is implicated in the induction of ischemic neuronal cell death, nor is it known what factors are responsible for inducing ICAM-1 expression in astroglial cells after tMCAO. Recently, we used immunohistochemistry to show that immunoreactivity for the p55 type I TNF receptor (TNFRI) was enhanced in astrocytes after tMCAO, and that astroglial TNFRI expression was prominent in the penumbral region a few days after tMCAO (Yin et al., to be submitted). It has been reported that TNF-a and another member of the superfamily to which it belongs, TWEAK, increased the expression of ICAM-1 in cultured astrocytes [13, 15, 19] . These results led us to speculate that TNFa and TWEAK might participate in the induction of astroglial ICAM-1 expression after tMCAO. Further investigation will be needed in order to determine the role of astroglial expression ICAM-1 and the factor(s) involved in the induction of astroglial ICAM-1 expression during ischemic stress.
In conclusion, ICAM-1-ir after ischemia was expressed in the endothelium of blood vessels and in the astrocytes. While the endothelial expression ICAM-1 overlapped with the region of neuronal cell death, the astroglial expression ICAM-1 was observed in the penumbra of infarct brain tissue, and did not overlap with the region of neuronal cell death.
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